These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 2197817)

  • 21. Clinical development of moricizine as an antiarrhythmic agent.
    Mahler SA; Borland RM
    Am J Cardiol; 1990 Feb; 65(8):11D-14D; discussion 68D-71D. PubMed ID: 2407088
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dose effect of moricizine on suppression of ventricular arrhythmias.
    Morganroth J
    Am J Cardiol; 1990 Feb; 65(8):26D-31D; discussion 68D-71D. PubMed ID: 1689534
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and tolerance of Ethmozine (moricizine HCl) in placebo-controlled trials.
    Morganroth J; Pratt CM; Kennedy HL; Singh SN; Platt ML; Baker BJ; Mason DT
    Am J Cardiol; 1987 Oct; 60(11):48F-51F. PubMed ID: 3310585
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ethacizin: a new efficacious Soviet antiarrhythmic drug of the phenothiazine group.
    Rosenshtraukh LV; Shugushev KK; Smetnev AS
    Am Heart J; 1986 Nov; 112(5):932-9. PubMed ID: 3535466
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of Ethmozine (moricizine HCl) on ventricular function using echocardiographic, hemodynamic and radionuclide assessments.
    Pratt CM; Podrid PJ; Seals AA; Young JB; Hession M; Lampert S; Quiñones M; Lown B
    Am J Cardiol; 1987 Oct; 60(11):73F-78F. PubMed ID: 3310589
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiarrhythmic drug therapy (Part 2). Benefits and hazards.
    Podrid PJ
    Chest; 1985 Oct; 88(4):618-24. PubMed ID: 3930162
    [No Abstract]   [Full Text] [Related]  

  • 27. Moricizine: pharmacodynamic, pharmacokinetic, and therapeutic profile of a new antiarrhythmic.
    Vanerio G; Maloney JD
    Cleve Clin J Med; 1992; 59(1):79-86. PubMed ID: 1551218
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiarrhythmic drug therapy for suppression of ventricular arrhythmia: experience with 122 patients treated for two years.
    Salerno DM; Fifield J; Hodges M
    J Clin Pharmacol; 1990 Mar; 30(3):226-34. PubMed ID: 2312780
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of moricizine in malignant ventricular arrhythmias.
    Horowitz LN
    Am J Cardiol; 1990 Feb; 65(8):41D-46D; discussion 68D-71D. PubMed ID: 1689535
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiarrhythmic drug therapy. Recent advances and current status.
    Somberg J
    Cardiology; 1985; 72(5-6):329-48. PubMed ID: 2866841
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New antiarrhythmic drugs: their place in therapy.
    Keefe DL; Kates RE; Harrison DC
    Drugs; 1981 Nov; 22(5):363-400. PubMed ID: 6800757
    [No Abstract]   [Full Text] [Related]  

  • 32. The events surrounding the removal of encainide and flecainide from the Cardiac Arrhythmia Suppression Trial (CAST) and why CAST is continuing with moricizine.
    Bigger JT
    J Am Coll Cardiol; 1990 Jan; 15(1):243-5. PubMed ID: 2104884
    [No Abstract]   [Full Text] [Related]  

  • 33. A symposium: Pharmacological management of ventricular arrhythmias--current status in the role of moricizine HCl. October 19-22, 1989, Scottsdale, Arizona. Proceedings.
    Am J Cardiol; 1990 Feb; 65(8):1D-71D. PubMed ID: 2407087
    [No Abstract]   [Full Text] [Related]  

  • 34. Comparative effect of disopyramide and ethmozine in suppressing complex ventricular arrhythmias by use of a double-blind, placebo-controlled, longitudinal crossover design.
    Pratt CM; Young JB; Francis MJ; Taylor AA; Norton HJ; English L; Mann DE; Kopelen H; Quinones MA; Roberts R
    Circulation; 1984 Feb; 69(2):288-97. PubMed ID: 6360413
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predicting mortality after myocardial infarction from the response of RR variability to antiarrhythmic drug therapy.
    Bigger JT; Rolnitzky LM; Steinman RC; Fleiss JL
    J Am Coll Cardiol; 1994 Mar; 23(3):733-40. PubMed ID: 7509355
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Comparative study of the effectiveness of ethacizine, etmozin and Ritmilen in patients with ventricular rhythmic disorders].
    Smetnev AS; Ponomarenko EL; Koltunova MI; Shugushev KhKh
    Kardiologiia; 1987 May; 27(5):24-6. PubMed ID: 2443743
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Complex ventricular arrhythmias associated with the mitral valve prolapse syndrome. Effectiveness of moricizine (Ethmozine) in patients resistant to conventional antiarrhythmics.
    Pratt CM; Young JB; Wierman AM; Borland RM; Seals AA; Leon CA; Raizner A; Quinones MA; Roberts R
    Am J Med; 1986 Apr; 80(4):626-32. PubMed ID: 3515932
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New directions in antiarrhythmic drug therapy.
    Somberg JC
    Am J Cardiol; 1984 Aug; 54(4):8B-17B. PubMed ID: 6147082
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Electrophysiological mechanisms of the anti-arrhythmia action of ethacizin].
    Malakhov VI; Golitsyn SP; Sokolov SF; Smetnev AS
    Biull Vsesoiuznogo Kardiol Nauchn Tsentra AMN SSSR; 1986; 9(2):112-6. PubMed ID: 3541960
    [No Abstract]   [Full Text] [Related]  

  • 40. Natural history of potentially lethal ventricular arrhythmias in patients treated with long-term antiarrhythmic drug therapy.
    Kennedy HL; Sprague MK; Homan SM; Seiler SM; Wiens RD; Janosik DL; Redd RM; Buckingham TA
    Am J Cardiol; 1989 Dec; 64(19):1289-97. PubMed ID: 2686388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.